Contrary to assumptions, once-a-day pills for combating HIV are actually less expensive than multi-tablet regimens and also offer an added bonus — patient adherence is greater, which suggests healthier outcomes, according to a new analysis of pharmacy claims.

To wit, overall medicine costs for patient taking single-tablet regimens were $6,100 less a year when compared regimens requiring multiple pills, among those who were taking the pills as they should. On average, health plans would save $4,162 per patient each year if they switched to clinically equivalent single-tablet regimens. Meanwhile, patient adherence was nearly 75 percent among those taking once-daily pills versus 65 percent for those on multi-tablet regimens.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • After this careful explanation, the takeaway seems to be “spend more, save more.” (More money, more people … other?) This post will need a second or third reading to fully understand this conundrum.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy